- Home
- EOSE vs ETNB Comparison
EOSE vs ETNB Comparison
Compare EOSE & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- ETNB
- Stock Information
- Founded
- EOSE 2008
- ETNB 2018
- Country
- EOSE United States
- ETNB United States
- Employees
- EOSE N/A
- ETNB N/A
- Industry
- EOSE Industrial Machinery/Components
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- EOSE Miscellaneous
- ETNB Health Care
- Exchange
- EOSE Nasdaq
- ETNB Nasdaq
- Market Cap
- EOSE 1.2B
- ETNB 1.0B
- IPO Year
- EOSE N/A
- ETNB 2019
- Fundamental
- Price
- EOSE $4.15
- ETNB $10.11
- Analyst Decision
- EOSE Strong Buy
- ETNB Strong Buy
- Analyst Count
- EOSE 3
- ETNB 8
- Target Price
- EOSE $22.00
- ETNB $26.43
- AVG Volume (30 Days)
- EOSE 16.5M
- ETNB 2.0M
- Earning Date
- EOSE 05-06-2025
- ETNB 05-01-2025
- Dividend Yield
- EOSE N/A
- ETNB N/A
- EPS Growth
- EOSE N/A
- ETNB N/A
- EPS
- EOSE N/A
- ETNB N/A
- Revenue
- EOSE $19,462,000.00
- ETNB N/A
- Revenue This Year
- EOSE $936.20
- ETNB N/A
- Revenue Next Year
- EOSE $175.46
- ETNB N/A
- P/E Ratio
- EOSE N/A
- ETNB N/A
- Revenue Growth
- EOSE 37.60
- ETNB N/A
- 52 Week Low
- EOSE $0.66
- ETNB $4.16
- 52 Week High
- EOSE $7.36
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- EOSE 34.74
- ETNB 68.32
- Support Level
- EOSE $5.57
- ETNB $8.94
- Resistance Level
- EOSE $6.11
- ETNB $9.70
- Average True Range (ATR)
- EOSE 0.48
- ETNB 0.73
- MACD
- EOSE -0.33
- ETNB 0.14
- Stochastic Oscillator
- EOSE 3.60
- ETNB 93.20
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).